Concepedia

Author

Durga Kanigicherla

University of ManchesterORCID

Also Known As

D Kanigicherla, D. Kanigicherla, Durga A K Kanigicherla, Durga A Kanigicherla, Durga A.K. Kanigicherla, Durga AK Kanigicherla, Durga AK. Kanigicherla, Durga Anil K Kanigicherla, Durga Anil K. Kanigicherla, Durga Anil Kanigicherla

68

Publications

1.4K

Citations

14

H-Index

9

Concepts

All Affiliations

University of ManchesterManchester University NHS Foundation TrustManchester Academic Health Science CentreManchester Royal InfirmaryUniversity of Leicester
DK

About

Durga Kanigicherla is an author at University of Manchester specializing in nephrology, chronic kidney disease, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

543

2

Nephrology

2

2

543

3

Pathology

2

2

543

4

Immunology

1

1

340

5

Autoimmune Disease

1

1

340

Durga Kanigicherla

×

14

Publications

1.1K

Citations

12

H-Index

YearCitations

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy

Durga Kanigicherla, Jennet Gummadova, Edward A. McKenzie,

Kidney International

2013

340

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink,

The Lancet

2023

224

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen,

Kidney International

2022

205

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers,

The Lancet

2023

203

Long-term outcomes of persistent disease and relapse in primary membranous nephropathy

Durga Kanigicherla, Colin D. Short, Stephen A. Roberts,

Nephrology Dialysis Transplantation

2016

35

Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model

Patrick Hamilton, Durga Kanigicherla, Michael Venning,

Nephrology Dialysis Transplantation

2018

25

Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New‐incident and relapsing primary membranous nephropathy

Durga Kanigicherla, Patrick Hamilton, Krystyna Czapla,

Nephrology

2016

18

Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti‐PLA<sub>2</sub>R positive primary membranous nephropathy

Patrick Hamilton, Durga Kanigicherla, Prasanna Hanumapura,

Journal of Clinical Apheresis

2017

15

Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?

Omar Ragy, Vilma Rautemaa, Alison Smith,

PLoS ONE

2023

15

Non-invasive cardiac stress studies may not offer significant benefit in pre-kidney transplant evaluation: A retrospective cohort study

Durga Kanigicherla, Talvinder Bhogal, Katie Stocking,

PLoS ONE

2020

14

Page 1